Kymera Therapeutics Shares Fall After Q3 Loss, Lower Revenue

MT Newswires Live

Oct 31, 2024

Kymera Therapeutics (KYMR) shares were down over 1% in recent Thursday trading after the company reported a Q3 loss, while its collaboration revenue decreased year-over-year and fell short of analyst expectations.

The company reported a Q3 net loss of $0.82 per diluted share, compared with a loss of $0.90 a year earlier.

Analysts polled by Capital IQ expected a $0.84 loss.

Collaboration revenue for the quarter ended Sept. 30 fell to $3.7 million from $4.7 million a year earlier.

Analysts surveyed by Capital IQ expected $10.3 million.

In August, the company raised about $247 million in net proceeds from an equity offering. Kymera said Thursday it extended its cash runway into mid-2027 with the proceeds.

Price: 46.97, Change: -0.70, Percent Change: -1.47

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2479039960"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479039960\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2479039960?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 22:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479039960","market":"nz","top_or_hot":-1,"title":"Kymera Therapeutics Shares Fall After Q3 Loss, Lower Revenue","media":"MT Newswires Live","content":"<html><body><p> Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (KYMR) shares were down over 1% in recent Thursday trading after the company reported a Q3 loss, while its collaboration revenue decreased year-over-year and fell short of analyst expectations.</p><p>The company reported a Q3 net loss of $0.82 per diluted share, compared with a loss of $0.90 a year earlier.</p><p>Analysts polled by Capital IQ expected a $0.84 loss.</p><p>Collaboration revenue for the quarter ended Sept. 30 fell to $3.7 million from $4.7 million a year earlier.</p><p>Analysts surveyed by Capital IQ expected $10.3 million.</p><p>In August, the company raised about $247 million in net proceeds from an equity offering. Kymera said Thursday it extended its cash runway into mid-2027 with the proceeds.</p><p>Price: 46.97, Change: -0.70, Percent Change: -1.47</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kymera Therapeutics Shares Fall After Q3 Loss, Lower Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKymera Therapeutics Shares Fall After Q3 Loss, Lower Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-31 22:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (KYMR) shares were down over 1% in recent Thursday trading after the company reported a Q3 loss, while its collaboration revenue decreased year-over-year and fell short of analyst expectations.</p><p>The company reported a Q3 net loss of $0.82 per diluted share, compared with a loss of $0.90 a year earlier.</p><p>Analysts polled by Capital IQ expected a $0.84 loss.</p><p>Collaboration revenue for the quarter ended Sept. 30 fell to $3.7 million from $4.7 million a year earlier.</p><p>Analysts surveyed by Capital IQ expected $10.3 million.</p><p>In August, the company raised about $247 million in net proceeds from an equity offering. Kymera said Thursday it extended its cash runway into mid-2027 with the proceeds.</p><p>Price: 46.97, Change: -0.70, Percent Change: -1.47</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2479039960","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479039960","pubTimestamp":1730384655,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kymera Therapeutics  shares were down over 1% in recent Thursday trading after the company reported a Q3 loss, while its collaboration revenue decreased year-over-year and fell short of analyst expectations.The company reported a Q3 net loss of $0.82 per diluted share, compared with a loss of $0.90 a year earlier.Analysts polled by Capital IQ expected a $0.84 loss.Collaboration revenue for the quarter ended Sept. 30 fell to $3.7 million from $4.7 million a year earlier.Analysts surveyed by Capital IQ expected $10.3 million.In August, the company raised about $247 million in net proceeds from an equity offering. Kymera said Thursday it extended its cash runway into mid-2027 with the proceeds.Price: 46.97, Change: -0.70, Percent Change: -1.47","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","KYMR":"Kymera Therapeutics, Inc."},"translate_title":"Kymera Therapeutics第三季度亏损、收入下降后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"KYMR":1},"content_text":"Kymera Therapeutics (KYMR) shares were down over 1% in recent Thursday trading after the company reported a Q3 loss, while its collaboration revenue decreased year-over-year and fell short of analyst expectations.The company reported a Q3 net loss of $0.82 per diluted share, compared with a loss of $0.90 a year earlier.Analysts polled by Capital IQ expected a $0.84 loss.Collaboration revenue for the quarter ended Sept. 30 fell to $3.7 million from $4.7 million a year earlier.Analysts surveyed by Capital IQ expected $10.3 million.In August, the company raised about $247 million in net proceeds from an equity offering. Kymera said Thursday it extended its cash runway into mid-2027 with the proceeds.Price: 46.97, Change: -0.70, Percent Change: -1.47","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}